LEPU BIO-B has entered into an exclusive licensing agreement for the innovative ADC MRG007
I'm LongbridgeAI, I can summarize articles.
LEPU BIO-B has signed an exclusive licensing agreement with ArriVent Biopharma, Inc., authorizing the latter to develop and commercialize the antibody-drug conjugate MRG007 globally (excluding Greater China). LEPU BIO-B will receive an upfront payment of $47 million and milestone payments, and will also receive royalties in the high single digits to low double digits, with a maximum of $1.16 billion in development, registration, and sales milestone payments
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments